FDA Shelves Priority Voucher Pilot After 22 Drug Vouchers

Twenty-two drugs entered the FDA’s National Priority Voucher pilot; 12 received approval, and sources said the program accelerated approval by eight months or more for several products.

The result matters because the pilot promised to compress final application reviews from 10–12 months to one or two months. Since Commissioner Marty Makary resigned on May 12, 2026, the FDA has issued no new vouchers, and the executive council of political appointees that managed reviews has gone dormant, according to a Nov. 12, 2026 Reuters report.

What changed after May 2026?

FDA leadership told companies that the agency is not moving forward with the program but will keep existing applications open. Once submitted, those applications do not advance, according to sources familiar with the matter.

Rich Danker, a former assistant secretary at the Department of Health and Human Services, called the initiative a quiet phaseout after Makary’s departure. FDA spokesperson Emily Hilliard said the pilot remains ongoing and that the agency is reviewing feedback from a June public hearing to refine the framework.

The combination supports a de facto stop in new issuance despite the FDA’s public description. Career scientists, not the former council, now oversee review timelines for nine drugs still in the program.

What evidence supports faster approvals?

The program began on June 17, 2025, for products aligned with national priorities, including urgent unmet health needs. Makary said its common-sense approach would let companies submit most of a drug application before a clinical trial ended, reducing regulatory inefficiency.

Of the 22 vouchers, 12 products received approval, including five after Makary left. Nine drugs remain in the program, with FDA career scientists overseeing their timelines after the governance shift.

The pilot’s one-to-two-month target applied to final application review, not clinical development. The eight-month acceleration claim concerns time to approval, and the source gives no comparison method, denominator for “several” products or development-time adjustment.

The source also does not explain the disposition of the remaining one of the 22 drugs after 12 approvals and nine continuing reviews. The operational account relies on unnamed sources, while named records, a comparison group and a calculation method are absent, preventing independent reproduction of the timing estimates.

What did the executive council change on Tzield?

The review of Sanofi’s diabetes drug Tzield shows the council’s role. Former acting drug center director Tracy Beth Hoeg withheld approval and raised safety objections at three council meetings between October 2025 and April.

After Hoeg and Makary left, agency staff granted Tzield accelerated approval in June. Hoeg said the trial showed “minimal at most” benefit against safety risks; Sanofi said the FDA concluded that benefits outweighed risks.

The source does not supply the trial’s sample size, endpoints, follow-up period, funder or statistical analysis. It therefore cannot support an independent comparison of benefit or risk.

University of Pennsylvania health policy professor Holly Fernandez Lynch characterized the program as the worst of both worlds, citing political-influence risk and limited practical benefit because many drugs could have used other expedited pathways.

Without counts of overlapping designations, the report cannot show whether the voucher shortened approval for Tzield or merely added another route alongside existing ones.

How did the pilot change development and launch work?

The pilot required sponsors to have chemistry, manufacturing and controls (CMC) packages and quality systems inspection-ready before submission. That requirement made regulatory documentation and inspection preparation prerequisites before FDA review could begin.

Henrik Johanning, senior vice president for Quality & Strategy at Epista Life Science, said: “When review windows shrink from 10 to 12 months to as little as 1 to 2 months, the entire model for launch readiness changes.”

The supplied account gives no company examples or timing dataset for Johanning’s assessment, so his statement functions as an operational warning rather than a measured sector result. Sponsors that rebuilt launch plans around voucher timing may now face conventional review schedules.

Teams cannot assume that inspection-ready quality files and CMC packages become unnecessary if the accelerated route disappears. They must identify launch activities sequenced to a one- or two-month review window and update near-term resource, budget and portfolio assumptions accordingly.

Which cases show the disruption now?

The two most recent voucher applications cleared for new drugs—Merck’s cholesterol pill Lipfendra and Revolution Medicines’ pancreatic cancer drug Rasonque—did not reach the executive council. FDA career scientists oversee the nine continuing reviews.

Merck KGaA’s fertility treatment Pergoveris received a voucher through a drug-pricing agreement with the administration. It remained unapproved three months after the FDA accepted its final application.

These cases show a gap between voucher status and review speed: a sponsor can hold a voucher or accepted filing without receiving the compressed review schedule that justified launch preparation around it.

Can the FDA stabilize the framework?

Policy instability extends beyond this pilot. When Makary resigned, many of his acceleration initiatives had not completed formal rulemaking, leaving them vulnerable to reversal. The FDA has since replaced the acting heads of its drug and biologics review centers and has had no commissioner since May.

Any revival would require more than issuing vouchers: sponsors need a named review owner, current timelines and evidence that the compressed schedule will survive leadership changes. For R&D leaders, the immediate test is the nine pending drugs: without an active council, new vouchers or a revised framework, launch plans should revert to conventional FDA timing while retaining contingency for a formal restart.